Zobrazeno 1 - 10
of 36
pro vyhledávání: '"ANA CVETANOVIC"'
Autor:
Ivan Petkovic, Miljan Krstic, Ivica Pejcic, Svetislav Vrbic, Slavica Stojnev, Ana Cvetanovic, Mirjana Balic, Mirjana Todorovic
Publikováno v:
Turkish Journal of Hematology, Vol 31, Iss 3, Pp 315-316 (2014)
Externí odkaz:
https://doaj.org/article/92dd142774a1479f9c8728508450cbbb
Autor:
LAZAR S. POPOVIC, GORANA MATOVINA-BRKO, MAJA POPOVIC, KEVIN PUNIE, ANA CVETANOVIC, MATTEO LAMBERTINI
Publikováno v:
Oncology Research. 31:221-238
Publikováno v:
Srpski arhiv za celokupno lekarstvo. 150:716-720
Introduction. Recommended biological agents for the first-line treatment of left-sided metastatic colorectal cancer (mCRC) without mutations in RAS/BRAF genes are cetuximab or panitumumab, while for rightsided mCRC bevacizumab is advised instead. For
Publikováno v:
Acta Medica Medianae. 60:38-47
Autor:
Nikola Zivkovic, Miloš Kostić, Milan Spasić, Dane Krtinić, Tijana Denčić, Maja Jovičić-Milentijević, Ana Cvetanovic, Milica Petrović, Miloš Trajković
Publikováno v:
Archives of Biological Sciences, Vol 73, Iss 1, Pp 65-72 (2021)
Salivary gland tumors are neoplasms characterized by a high level of pleomorphism and histological overlap. One tumor may contain several cell types; therefore, it is necessary to include immunohistochemical staining, as well as morphometric analysis
Publikováno v:
Acta medica Medianae (2020) 59(2):5-13
The novel concept of immune thrombocytopenia (ITP) pathogenesis is focused on CD4+ T cells, currently considered indispensable in stimulating B cells to produce anti-platelet antibodies. In this in vitro study, we have investigated CD4+ T cell profil
Autor:
Joyce O'Shaughnessy, Susana Sousa, Josefina Cruz, Lesley Fallowfield, Päivi Auvinen, Catarina Pulido, Ana Cvetanovic, Sharon Wilks, Leonor Ribeiro, Mauricio Burotto, Dirk Klingbiel, Dimitri Messeri, Ari Alexandrou, Peter Trask, Judy Fredriksson, Zuzana Machackova, Ljiljana Stamatovic, Ernesto Korbenfeld, Jorge Nadal, Helio Pinczowski, Felipe J. Cruz, Gustavo Sousa, Aline C. Goncalves, Gisah Guilgen, Antti Jekunen, Winne Yeo, Chi K. Cheng, Hikmat A. Razeq, Fadi Karak, Fadi Farhat, Servando C. Huerta, Brizio M. Jaime, Juan Feregrino, Omar Castillo-Fernandez, Juan C. Alcedo, Maria Dionisio, Salha Bujassoum, Hatoon Bakhraibah, Alvaro R. Lescure, Camilla Wendt, Sara Margolin, Helena G. Björneklett, Michelina Cairo, Shaker Dakhil, Nguyet Le-Lindqwister, Ling Ma, Kristi J. McIntyre, Joyce O’Shaughnessy, Svetislava J. Vukelja, Donald Richards, John Wallmark
Aim: The aim of the study was to assess patient preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in patients with HER2-positive early breast cancer in PHranceSCa (NCT03674112). Materials a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efa4c6a666e370a233289e49fa120291
https://zenodo.org/record/5196150
https://zenodo.org/record/5196150
Publikováno v:
Acta Facultatis Medicae Naissensis. 37:349-358
The aim of the research was to investigate prognostic factors in patients with resected colorectal liver metastases (CLMs) after biological and chemotherapy, which made initially unresectable disease suitable for resection. Sixty-six patients with re
Autor:
Stasa Krasic, Milos Stojanovic, Ana Cvetanovic, Andrija Ćosić, Miloš Trajković, Nikola Živković, Vojkan Lazić, Dragan Krasić
Publikováno v:
Srpski Arhiv za Celokupno Lekarstvo, Vol 148, Iss 5-6, Pp 328-332 (2020)
Introduction/Objective. Nasolacrimal duct obstruction with consequent epiphora and the development of dacryocystitis (DC) represents a common pathological entity in the clinical practice of ophthalmologists and maxillofacial surgeons. The etiology of
Autor:
Dragana Petrovic, Maja Popović, Gorana Matovina-Brko, Ivan Nikolic, Milica Popovic, Biljana Kukic, Ana Cvetanovic, Lazar Popovic
Publikováno v:
World Journal of Stem Cells
Relapsed or refractory non-Hodgkin's lymphomas, especially diffuse large B-cell lymphoma as well as relapsed or refractory Hodgkin lymphomas are hard-to-treat diseases. Patients who do not respond to initial therapy or experience relapse are treated